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Objective: The authors explored the association between abuse
of 3,4-methylenedioxymethamphetamine (MDMA, or “Ecstasy”)
and high-risk sexual behaviors among gay and bisexual men.
Method: An anonymous questionnaire was completed by 169
gay and bisexual men at three New York City dance clubs. The
questionnaire covered demographic indices, use of MDMA and
other drugs, and history of high-risk sexual behaviors.
Results: About one-third of the respondents reported MDMA
use at least monthly. MDMA use was strongly and significantly
associated with a history of recent unprotected anal inter-
course. This association remained equally strong even after
controlling for age, ethnicity, and all other forms of drug use, in-
cluding alcohol.
Conclusions: MDMA abuse, and its strong association with high-
risk sexual behaviors, appears to represent important unexplored
public health problems among some gay or bisexual men.
(Am J Psychiatry 2000; 157:1162–1164)
Over the last 20 years, abuse of 3,4-methylene-
dioxymethamphetamine (MDMA, or “Ecstasy”) has in-
creased sharply, especially at late-night dance clubs and at
dance parties known as “raves” (1). This abuse represents a
potential public health problem, since the drug may cause
lasting neurotoxicity (2) and psychopathology (3). Yet no
published studies, to our knowledge, have addressed the
associations between MDMA abuse, sexual orientation,
and high-risk sexual behaviors. These associations may be
important, since MDMA may increase energy, sexual re-
ceptivity (4), and “warmth and openness”(5), which has
led some to call it the “love drug”(1) or the “hug drug”(5).
To provide preliminary data in this area, we surveyed gay
and bisexual men recruited from dance clubs in New York
City.
Method
We distributed an anonymous one-page self-report question-
naire to 180 men as they entered three predominantly gay New
York City dance clubs on three successive Saturday nights. The
questionnaire, available from Dr. Klitzman, covered age; self-re-
ported sexual orientation; current frequency of MDMA use, other
illicit drug use, and alcohol use; history of sexually transmitted
diseases; HIV status (if known to the respondent); and frequency
of insertive and receptive anal intercourse without a condom
within the past year. The questionnaire was developed for the
study and did not incorporate previously validated questions.
The study was approved by the Columbia University Department
of Psychiatry institutional review board.
Results
Since questionnaire respondents were asked to com-
plete the questionnaire immediately upon receiving it, all
of the 180 questionnaires that we distributed were col-
lected. However, only 172 (96%) of these were evaluable;
two were filled out incoherently, and six others failed to
specify the respondent’s sexual activity or frequency of
MDMA use. Submitted questionnaires that supplied at
least these two items were considered evaluable. Of the
172 evaluable respondents, 119 (69%) described them-
selves as gay, 50 (29%) as bisexual, and three (2%) as het-
erosexual men. We examined the 169 subjects who identi-
fied themselves as gay or bisexual. These men were a
mean age of 24.2 years (SD=6.4, range=16–44, median=
22); 95 (56%) described themselves as white, 34 (20%) as
Latino, seven (4%) as black, five (3%) as Asian-Pacific
Islanders, and 28 (17%) as “other” or no answer. About
one-third of these men reported at least monthly use of
MDMA—a proportion greater than that for any other cat-
egory of illicit drugs except marijuana, which only slightly
exceeded MDMA in frequency (Table 1).
Of 155 respondents who answered the question about
insertive anal intercourse, 11 (7%) reported that they had
engaged in this behavior “often” in the past year, 23 (15%)
engaged in it “sometimes,” 37 (24%) reported that they
“rarely” engaged in the behavior, and 84 (54%) reported
that they “never” engaged in the behavior during the past
year. For the 159 respondents who answered the receptive
anal intercourse question, the corresponding figures were
eight (5%), 19 (12%), 46 (29%), and 86 (54%). Of 152 re-
spondents who answered the question regarding HIV sta-
tus, 104 (68%) reported that they had been tested; of these,
four (4%) reported that they were HIV positive, 82 (79%)
reported that they were HIV negative, and 18 (17%) left the
question blank. Of the 82 self-reported HIV-negative men,
36 (44%) reported engaging in insertive or receptive anal
intercourse within the last year, as compared to 29 (60%)
of the 48 who reported not having been HIV tested (p=
0.051, Fisher’s exact test, two-tailed).
We defined “high-risk sexual behavior” as any unpro-
tected insertive or receptive anal intercourse in the past
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year. Of 157 respondents who could be scored for presence
or absence of high-risk sexual behavior, 90 (57%) reported
that they had engaged in this behavior in the past year. As
shown in Table 1, of all the categories of drugs used at least
monthly or more by 10 or more respondents, only MDMA
was significantly associated with high-risk sexual behav-
ior. To analyze this association further, we defined binary
categories of “frequent MDMA use” for respondents re-
porting at least monthly MDMA use and “infrequent use
or nonuse” for all others. We then assessed the association
between high-risk sexual behavior and frequent MDMA
use, first by computing the risk ratios and subsequently by
examining odds ratios by means of a logistic regression
analysis, both unadjusted and adjusted for the effects of
age (under 20, 20–24, 25–29, over 30); ethnicity (Caucasian
versus non-Caucasian); sexual orientation (gay versus bi-
sexual); club attended; and frequency of alcohol use (less
than once/week versus at least weekly) and other drug use
(less than once/week versus at least weekly use of any
illicit drug).
We found a strong association between frequent MDMA
use and high-risk sexual behavior. The risk ratio for high-
risk sexual behavior among frequent versus nonfrequent
MDMA users was 1.37 (95% confidence interval [CI]=1.10–
1.70). In view of the 50% prevalence of high-risk sexual be-
havior even among nonfrequent MDMA users, this risk ra-
tio reflects an alarming absolute increase in risk of 23% as-
sociated with frequent MDMA use. The unadjusted odds
ratio was 2.77 (95% CI=1.35–5.65) for high-risk sexual be-
havior and changed little when adjusted for other covari-
ates (2.87, 95% CI=1.20–6.84). It is of interest that neither
frequent alcohol use nor frequent use of other drugs was
significantly associated with high-risk sexual behavior
(risk ratios of 1.03 [95% CI=0.69–1.50] and 1.03 [95% CI=
0.81–1.31], respectively), which suggests that the associa-
tion between frequent MDMA use and high-risk sexual be-
havior was not attributable to the confounding effects of
other drug use.
Discussion
In an anonymous questionnaire survey of 169 self-re-
ported gay or bisexual men at three New York City dance
clubs, we found strikingly high rates of MDMA use that ex-
ceeded rates for all other illicit drugs except marijuana.
Moreover, MDMA use was strongly and significantly asso-
ciated with high-risk sexual behaviors, and this associa-
tion remained equally strong even after controlling for al-
cohol use, all other forms of illicit drug use, and various
demographic measures.
The reasons for the association between MDMA use and
high-risk sexual behaviors remain to be investigated. Al-
though high-risk sexual behaviors have been linked to the
use of other illicit drugs (6, 7), possibly as a result of “sen-
sation seeking” (8) or altered judgment (6), the striking
and seemingly independent association of high-risk sex
with use of MDMA remains unexplained. It is possible that
individuals who abuse MDMA harbor high premorbid
tendencies for risk-taking or that subcultural influences
from other MDMA users encourage higher levels of risky
sexual behaviors. Alternatively, MDMA-induced intoxica-
tion, residual neurotoxicity (7), or psychopathology (6)
may compromise users’ judgments about the hazards of
their sexual behavior.
Several limitations of this study should be considered.
First, some club patrons did not stop to accept a question-
naire at the entrance, thus creating possible selection bias.
Second, gay and bisexual men at New York City dance
clubs cannot be assumed to be representative of gay and
bisexual men in the United States as a whole. Third, since
this was not an interview study, we were unable to validate
formally the questionnaire responses or query subjects di-
rectly about the relationship between high-risk behavior
and each of the substances used. Nevertheless, the find-
ings of this pilot study suggest that frequent MDMA use
and its association with high-risk sexual behaviors may
represent largely unexplored public health problems
among some gay or bisexual men.
TABLE 1. Substances and Frequency of Use Reported by 169 Gay or Bisexual Men Surveyed at Three New York City Dance







Four or More 
Times/Week
One to Three 
Times/Week
At Least Once/Month but 
Less Than Once/Week




N % N % N % N % N %
MDMA 11 7 20 12 26 15 31 18 81 48 0.02
Alcohol 43 25 60 36 36 21 17 10 13 8 0.73
Marijuana 19 11 23 14 21 12 38 22 68 40 0.35
Cocaine or “crack” 2 1 5 3 20 12 27 16 115 68 0.26
Inhaled nitrites 3 2 8 5 10 6 17 10 131 78 0.47
Hallucinogens 5 3 2 1 5 3 30 18 126 75 0.18
Methamphetamine 1 1 0 0 12 7 20 12 136 80 0.44
Other “uppers” 2 1 7 4 9 5 15 9 136 80 0.06
Ketamine 9 5 16 9 16 9 23 14 105 62 0.11
a Total N for each drug category may not total 169 because of missing data.
b Only drugs used at least monthly by 10 or more of the subjects are listed within the table. Other reported substances used at least monthly
were sedatives (5%, N=9), γ-hydroxybutyrate (“GHB”) (4%, N=6), heroin and other opiates (3%, N=5), and phencyclidine (2%, N=4).
c Values represent p values resulting from two-tailed Fisher’s exact tests.
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Brief Report
Lack of Interaction of Buprenorphine
With Flunitrazepam Metabolism
Tansel Kilicarslan, B.Sc., M.Sc.
Edward M. Sellers, M.D., Ph.D.
Objective: The authors’ goal was to determine if the reported
clinical adverse interaction of flunitrazepam and buprenor-
phine was caused by inhibition of drug metabolism.
Method: Inhibition of flunitrazepam metabolism by buprenor-
phine and norbuprenorphine were determined in three human
liver microsome preparations carrying the CYP2C19*1/*1 allele.
Omeprazole metabolism mediated by CYP2C19 and CYP3A4 was
used as a control reaction. Apparent Ki values were determined.
Results: Norbuprenorphine did not inhibit the metabolism of
flunitrazepam or omeprazole. Buprenorphine inhibited the for-
mation of CYP3A4-mediated pathways of 3-hydroxyfluni-
trazepam and omeprazole sulfone formation (Ki 118 and 16 µM)
in human liver microsomes. Corresponding values were 38 and
90 µM in cDNA-expressed CYP3A4 microsomes. Projected in vivo
inhibition of CYP3A4-mediated metabolism of flunitrazepam by
buprenorphine is 0.1%–2.5%. Estimated inhibition of buprenor-
phine N-dealkylation by flunitrazepam in vivo is 0.08%.
Conclusions: The clinical interaction of flunitrazepam and bu-
prenorphine is likely based on a pharmacodynamic mechanism.
(Am J Psychiatry 2000; 157:1164–1166)
Recently, Reynaud et al. (1) reported that the combina-
tion of buprenorphine and flunitrazepam resulted in unex-
pected deaths. A possible mechanism underlying such an
interaction would be inhibition of buprenorphine metabo-
lism by flunitrazepam or vice versa. Since buprenorphine
and flunitrazepam both undergo N-dealkylation by the
drug-metabolizing cytochrome P450 enzyme 3A4, it is pos-
sible that concomitant use of the two drugs could result in
higher than expected concentrations of either (or both) of
the drugs because of mutual competitive inhibition.
Buprenorphine is an opioid derivative of the morphine
alkaloid thebaine, used in the treatment of opiate addic-
tion. In humans, the principal route of buprenorphine
metabolism is by means of N-dealkylation of the N-cyclo-
propylmethyl group to norbuprenorphine by cytochrome
P450 3A4 (CYP3A4) (2, 3).
Flunitrazepam is a benzodiazepine derivative that is
primarily used as a sedative and hypnotic (4). The major
metabolites for flunitrazepam in humans are desmethyl-
flunitrazepam, 3-hydroxyflunitrazepam, and 7-amino-
flunitrazepam (5, 6). We have identified the major en-
zymes that mediate the formation of these metabolites as
CYP3A4 and the polymorphically expressed CYP2C19 (7).
CYP3A4 mediates 80% of the formation of 3-hydroxyfluni-
trazepam and approximately 40% of desmethylflunitra-
zepam formation. CYP2C19 is the major enzyme that cat-
alyzes desmethylflunitrazepam formation by contributing
to 60% of total metabolite formation.
